Neurocrine Biosciences Conference Call Summary Company Overview - **Company**: Neurocrine Biosciences (NasdaqGS:NBIX) - **Date**: March 09, 2026 - **Key Products**: INGREZZA and CRENESSITY Core Industry Insights - **Market Position**: Neurocrine has two approved products, INGREZZA and CRENESSITY, with a revenue guidance of $2.7 billion to $2.8 billion for INGREZZA in 2026, reflecting significant growth potential [8][11] - **Sales Force Expansion**: A recent expansion of the sales force is expected to enhance patient outreach and support for tardive dyskinesia treatment [8][10] Product Performance - **INGREZZA**: - Launched 9 years ago, still experiencing double-digit growth [8] - Expected to achieve nearly 10% growth in 2026, with volume growth projected at 14%-15% after accounting for price declines [61] - Currently, only 10% of the 800,000 patients with tardive dyskinesia are on VMAT2 inhibitors, indicating substantial market potential [61] - **CRENESSITY**: - First new treatment for congenital adrenal hyperplasia (CAH) in over 70 years, generating over $300 million in sales in its first year [9] - Targeting a patient population of approximately 20,000 with classic CAH, with an additional 60,000 to 80,000 with non-classic CAH [17] - The launch is considered one of the top 10% of rare disease launches historically [9] Financial Health - **Cash Position**: Neurocrine holds over $2.5 billion in cash with no debt, indicating strong financial stability [11] - **R&D Investment**: The company allocates around 35% of its revenue back into research and development, supporting a robust pipeline [10][86] Growth Strategies - **Patient Acquisition**: - Less than 50% of the initial 2,000 patients for CRENESSITY came from Centers of Excellence, indicating room for growth in this area [20] - The company is optimistic about increasing patient access through ongoing efforts and clinician engagement [20][28] - **Reimbursement Success**: - Over 80% of prescriptions for CRENESSITY are being reimbursed, with a strong foundation laid for reimbursement processes prior to launch [30][28] - The reimbursement landscape is favorable, with a manageable process for obtaining authorizations [28] Future Prospects - **Clinical Trials**: Two late-stage Phase 3 trials are underway, focusing on schizophrenia and depression, with results expected in 2027 and 2028 [10] - **Obesity Market Entry**: Neurocrine is exploring opportunities in the obesity space, leveraging its existing expertise and planning to initiate trials soon [86][82] Key Challenges - **Market Competition**: The company acknowledges the competitive landscape in obesity and is focused on differentiating its offerings [85] - **Investment Scrutiny**: There are concerns regarding high spending levels, but the company emphasizes long-term growth over short-term profitability [87][89] Conclusion Neurocrine Biosciences is positioned for significant growth with its innovative products and strong financial foundation. The company is actively expanding its market presence while investing in research and development to sustain its pipeline and address unmet medical needs.

Core Viewpoint - The strong trend in the mainland healthcare sector from last year is expected to continue into this year, with investors considering the value of more R&D pipelines when evaluating valuations [1] Group 1: Investment Strategy - Companies are now trading based more on actual execution capabilities rather than solely on licensing deal expectations [1] - Achieving returns that exceed the industry average this year will rely more on key data releases, actual transactions, and visibility on profit realization or turning points [1] Group 2: Sector Analysis - The outlook for CDMO companies is becoming more constructive due to accelerated growth, strong product cycles, limited geopolitical risks, and reasonable valuations [1] - The ratings for WuXi AppTec and WuXi AppTec Holdings have been upgraded to "Buy" [1] Group 3: Selective Strategy in Biotech and Pharma - A selective strategy is adopted for biotech and pharmaceutical companies, favoring those with key data releases and early data showing some promise, along with actual transaction expectations [1] - Companies such as Kelun-Biotech, Innovent Biologics, and Hansoh Pharmaceutical are viewed positively [1] Group 4: Medical Devices Sector - The medical devices sector maintains a neutral outlook, as the industry has bottomed out but requires time for gradual recovery [1] - Recommendations include buying Angelalign Technology and Weigao Group [1]

Financial Data and Key Metrics Changes - Novartis achieved high single-digit growth with an 8% increase in sales and a 14% rise in core operating income for the full year 2025, reaching a core margin of 40.1% [4][35] - For Q4, sales declined by 1%, while core operating income increased by 1%, with core EPS rising 2% to $2.03 [5][38] - Free cash flow reached an all-time high of CHF 17.6 billion, growing 8% year-over-year [35][39] Business Line Data and Key Metrics Changes - Kisqali sales grew 57% year-over-year to CHF 4.8 billion, with Q4 growth at 44% [6][7] - Kesimpta saw a 36% increase to $4.4 billion, with a 27% growth in Q4 [10] - Pluvicto achieved $2 billion in global sales, with a 75% increase in the U.S. [12] - Leqvio reached blockbuster status with 57% growth for the year [14] - Scemblix also reached blockbuster status with 87% growth in Q4 [15] Market Data and Key Metrics Changes - Kisqali's U.S. sales growth was 62%, with over 80% NBRX share in Germany for early breast cancer [7][9] - Kesimpta is leading in NBRX share in 9 out of 10 major markets outside the U.S. [10] - Pluvicto secured approvals in Japan and China, contributing to strong growth outside the U.S. [12] - Scemblix has a 41% NBRX share in the U.S. and 72% in the third-line setting across major markets [17] Company Strategy and Development Direction - Novartis aims to grow through the largest patent expiry in its history, focusing on key growth brands and pipeline replacement [6] - The company plans to continue investing in R&D while managing productivity improvements [43][44] - Novartis is committed to maintaining a 5%-6% sales CAGR from 2025 to 2030 [44][49] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving mid-single-digit sales growth in 2026 despite anticipated challenges from generic entries [43][44] - The company expects to return to a core margin of over 40% by 2029 [44] - Management highlighted the importance of pipeline advancements and upcoming pivotal readouts in 2026 [32][50] Other Important Information - Novartis has completed its CHF 15 billion share buyback program and initiated a new CHF 10 billion program [41] - The proposed dividend for 2025 is CHF 3.70 per share, marking a 6% increase [41][42] Q&A Session Questions and Answers Question: Insights on remibrutinib and FDA conversations - Management noted that remibrutinib has an approved label without liver safety discussions, and they plan to advocate for limited liver monitoring based on FDA feedback [53][54] Question: Commercial opportunities for remibrutinib in MS - Management indicated that the commercial opportunity will depend on data-driven results, with a significant market for oral options in MS [60][61] Question: Thoughts on Pelacarsen's event-based study risks - Management expressed confidence in the study's design and powering assumptions, despite lower than expected event rates [62][63] Question: Launch plans for Rhapsido and Ianalumab in an MFN world - Management acknowledged the importance of adjusting launch strategies for significant assets like Rhapsido and Ianalumab in the ex-U.S. market [73]

Financial Data and Key Metrics Changes - Revenue for the nine-month period was just over JPY 3.4 trillion, a decrease of 3.3% or -2.8% at constant exchange rate [11] - Core Operating Profit was JPY 971.6 billion, a year-on-year decrease of 3.4% at both actual effects and constant exchange rate [11] - Reported operating profit was JPY 422.4 billion, an increase of 1.2% [12] - Core EPS was JPY 428, and reported EPS was JPY 137 [12] - Adjusted free cash flow was JPY 625.9 billion, even after a $1.2 billion upfront payment to Innovent Biologics [12] Business Line Data and Key Metrics Changes - Growth and launch products represented over 50% of total revenue and grew 6.7% at constant exchange rate [12] - In GI, Entyvio grew 7.4% at constant exchange rate, with strong growth in Q3 due to a one-time gross-to-net drop [12][13] - Takhzyro in rare diseases slowed to 2.4% growth at constant exchange rate, impacted by new competing products in the U.S. [13] - Immunoglobulin growth was 4.3% year to date, driven by subcutaneous IG products [14] - Qdenga growth accelerated to 22.1%, primarily driven by Brazil [14] Market Data and Key Metrics Changes - Entyvio Pen is now on the formulary with all three large pharmacy benefit managers, achieving commercial coverage of more than 80% [13] - The impact of Medicare Part D redesign in the U.S. has affected IVIG sales, which are expected to normalize in Q4 [14] - Albumin growth returned to 1.3%, slower than expected due to softening demand in China [14] Company Strategy and Development Direction - The company is preparing for significant new product launches, focusing on oveporexton, rusfertide, and zasocitinib, expected to launch over the next 18 months [6][9] - The late-stage pipeline includes eight programs with the potential to transform the standard of care [10] - The company is committed to maintaining operational efficiency while investing in R&D for future growth [17] Management's Comments on Operating Environment and Future Outlook - Management revised revenue guidance to low single-digit decline at constant exchange rate due to stronger than anticipated Vyvanse generic erosion [18] - The company maintains full-year guidance for core operating profit and core EPS, emphasizing cost discipline [18] - Management expressed confidence in the potential of new product launches to drive future growth despite current challenges [20][41] Other Important Information - This earnings call marked Christophe Weber's last as a main presenter, with Julie Kim set to take over as CEO [29] - The company is undergoing organizational changes to enhance competitiveness and speed in preparation for multiple launches [31][55] Q&A Session Summary Question: Thoughts on next fiscal year and dividend policy - Management indicated it is too early to provide guidance for the next fiscal year, with the budget being finalized [39] - The company aims to maintain a progressive dividend policy, evaluating core EPS and cash flow to decide on potential increases [42] Question: Zasocitinib phase II outcomes and safety data - Data from UC and Crohn's disease phase II studies are expected this year, with ongoing studies assessing higher doses for efficacy [44][46] Question: Impact of MFN and organizational changes - Management does not support MFN, emphasizing that price controls could hinder future innovation [53] - Organizational changes focus on enhancing U.S. marketing and maintaining a strong oncology business unit [55] Question: Entyvio sales trends and IRA impact - Q3 sales performance was strong, with improved coverage in the U.S. [60] - The company is preparing for potential price negotiations under the IRA, with uncertainty regarding the extent of price cuts [62][63] Question: Takhzyro growth and competitive impact - Takhzyro continues to be the gold standard for HAE patients, but recent competitive entrants have impacted new starts [67] - Long-term efficacy data supports Takhzyro's market position despite current challenges [68]

Group 1 - The core viewpoint of the article is that Goldman Sachs has upgraded Biogen Inc. (BIIB.US) to a "Buy" rating with a target price of $225 after meeting with the company's management, who emphasized a cultural shift towards research and development and cost control to counteract the decline in its multiple sclerosis business and drive growth [1][1][1] - Goldman Sachs believes that Biogen is poised for a turning point this year, driven by catalysts in its research pipeline and the Leqembi product, along with strict cost control and a strategic focus on developing early-stage rare disease and/or immunology assets [1][1][1] Group 2 - Biogen's pre-market stock price increased by 1.26% to $171.45, following the positive news from Goldman Sachs [1][1] - The company's recent stock performance shows a closing price of $169.31, down 5.04%, with a trading volume of 3.6359 million shares [1][1] - Biogen's total market capitalization is approximately $24.838 billion, with a price-to-earnings ratio of 15.14 and a price-to-book ratio of 1.364 [1][1]

Financial Data and Key Metrics Changes - Alvotech reported total revenues of $420 million for the first nine months of 2025, representing a strong 24% year-on-year growth [22] - The company revised its full-year revenue guidance to a range of $570 million-$600 million and adjusted EBITDA to $130 million-$150 million following a Complete Response Letter (CRL) from the FDA [11][26] - Adjusted EBITDA for the first nine months was $68 million, or 16% margin, compared to 26% the previous year, driven by higher R&D investments [24] Business Line Data and Key Metrics Changes - Licensing revenues in Q3 were at a high level of $81 million, supporting a strong gross margin of 69% [21] - The product margin for Q3 was 27%, reflecting softness due to timing of orders and facility improvements [22] - Alvotech's revenue growth averaged 127% per year from 2021 to year-end 2024, with a projected compounded average growth rate of 94% from 2021 to the end of 2025 [12] Market Data and Key Metrics Changes - In the U.S., Alvotech holds the second-largest market share in the Humira biosimilar segment, with products being the fastest-growing in that category [13] - In Europe, the biosimilar Yukindra has seen average quarter-on-quarter growth of 12% over the last four quarters and holds top positions in several major EU markets [13] - The company expects 50% of Stelara's European market to transition to biosimilars by year-end [14] Company Strategy and Development Direction - Alvotech aims to lead the biosimilar market, having invested approximately $2 billion in building a global biosimilar company with integrated R&D and manufacturing [4] - The company has expanded its R&D capabilities with a new operational base in Sweden and has a pipeline targeting over $185 billion of originated markets [6] - The strategic focus for the next 18 months includes advancing the pipeline, executing multiple global launches, and driving cost optimization [27] Management Comments on Operating Environment and Future Outlook - Management expressed disappointment over the CRL but remains committed to resolving outstanding issues and anticipates approval of the BLA as early as the first half of 2026 [10] - The company expects strong growth in 2026, driven by committed orders for new launches and growth momentum in currently marketed products [27] - Management emphasized the importance of maintaining in-house R&D and manufacturing to ensure quality and compliance with regulatory standards [35] Other Important Information - Alvotech has five approved biosimilars and 12 other disclosed development programs, with additional cell lines developed for 15 valuable targets [6] - The company finalized the integration of Ivers-Lee, a Swiss-based assembly and packaging service provider, to increase capacity for finished product assembly [21] Q&A Session Summary Question: Can you explain the observations related to the CRL? - Management clarified that the observations were not repeat issues and that over 180 changes have been committed to the FDA, with 93% already completed [32][33] Question: How does the CRL impact conversations with customers? - Management noted that there has been no reduction in interest from clients, and they continue to keep key clients updated on quality system improvements [41] Question: What is the expected impact of the manufacturing process changes on revenue? - Management indicated that the revision in guidance reflects both production slowdowns and the timing of licensing agreements shifting to 2026, impacting Q4 EBITDA significantly [46] Question: What amendments have been made to production lines? - Management detailed improvements in manufacturing controls and documentation practices, with ongoing production expected to return to full capacity [52][56] Question: How will regulatory changes affect earlier stage biosimilars? - Management stated that they anticipated regulatory changes and adjusted their R&D strategy accordingly, positioning themselves well for future developments [62]

Core Viewpoint - Senxuan Pharmaceutical reported a revenue increase of 5.90% year-on-year for the first three quarters of 2025, driven by improved product quality and service, successful commercialization of new raw materials, and enhanced operational efficiency [1][2] Group 1: Financial Performance - For the first three quarters of 2025, Senxuan Pharmaceutical achieved a revenue of 411 million yuan, a year-on-year increase of 5.90% [1] - The net profit attributable to shareholders for the same period was 104 million yuan, reflecting a year-on-year growth of 13.45% [1] - In the third quarter alone, the company reported a revenue of 150 million yuan, marking a significant year-on-year increase of 29.45% [1] - The net profit for the third quarter was 35.736 million yuan, which is a remarkable year-on-year growth of 64.79% [1] Group 2: Growth Drivers - The revenue growth was attributed to three main factors: improved product quality and service leading to increased market share, successful commercialization of new raw materials, and ongoing internal management optimization [1] - The company plans to ensure long-term stable growth by advancing the overseas registration of both new and existing products, particularly in high-end regulatory markets in Europe and the United States [1] Group 3: R&D and Market Expansion - Research and development expenses decreased by 12.73% year-on-year, primarily due to some projects reaching maturity and reduced investment in early-stage projects [2] - Despite the decrease, the company emphasized that its commitment to R&D remains strong, focusing on high-potential therapeutic areas such as antiviral, anti-tumor, and anti-epileptic treatments [2] - The subsidiary, Luhua Senxuan, has successfully entered markets in engineering plastics, fibers, and pharmaceuticals, with plans to expand into new applications and markets, including Russia and Southeast Asia [2] - An industry standard for 1,3-Dioxolane, led by Luhua Senxuan, is set to be implemented in March 2026, which is expected to enhance the brand influence in the new materials sector [2]

Core Insights - The report from Ping An Securities indicates that BeiGene achieved a profit of $125 million in Q3 2025, with a total profit of $220 million for the first three quarters of 2025, compared to a loss of $493 million in the same period last year [1] - The global sales of the BTK inhibitor, Zebrutinib, reached $1 billion in Q3 2025, with total revenue of $2.78 billion for the first three quarters [1] - The company is making comprehensive advancements in the hematological oncology field, with rapid global rollout of Zebrutinib and steady progress in the development of BCL2 inhibitors and BTK CDAC [1] - BeiGene is continuously enriching its R&D pipeline through rapid concept validation, achieving progress in solid tumors and immune-inflammatory areas [1] - The revenue forecasts for 2025-2027 have been adjusted to 37.068 billion, 44.536 billion, and 52.231 billion yuan, respectively, from the previous forecasts of 36.407 billion and 43.954 billion yuan for 2025-2026 [1] - The company maintains a "recommended" rating [1]

Financial Data and Key Metrics Changes - For Q3 2025, the company recorded revenues of $16.7 billion, a decrease of 7% operationally compared to the same period last year, primarily driven by a decline in COVID products [23] - Reported diluted earnings per share (EPS) was $0.62, while adjusted diluted EPS was $0.87, exceeding expectations due to strong gross margin and cost management performance [24] - Adjusted gross margin for Q3 was approximately 76%, reflecting product mix and strong cost management [25] Business Line Data and Key Metrics Changes - Non-COVID product performance grew 4% operationally compared to the same period last year, with solid contributions from ELIQUIS, the VYNDAQEL family, and NURTEC [23][24] - The VYNDAQEL family achieved 7% year-over-year global operational growth, while NURTEC led the oral CGRP class in primary care penetration in the U.S. [14][15] - PADCEV achieved 13% year-over-year global operational growth, establishing itself as a standard of care for patients with locally advanced metastatic urothelial cancer [15] Market Data and Key Metrics Changes - In international markets, the company achieved 40% growth in total patients on treatment for the VYNDAQEL family [15] - The vaccines portfolio, particularly the PREVNAR family, saw 17% year-over-year international operational growth [16] - The company expects the lung cancer market to reach approximately $70 billion by 2023, with strong growth in its lung cancer portfolio [12] Company Strategy and Development Direction - The company is focused on strategic investments in innovation and growth, highlighted by the proposed acquisition of Metsera and the licensing agreement with 3SBio [6][8] - The company aims to enhance its R&D pipeline and commercial capabilities, particularly in the high-growth therapeutic area of obesity [8] - The recent agreement with the U.S. Government aims to lower prescription drug costs while allowing the company to focus on business and innovation [32] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's position to deliver value for patients and shareholders, despite challenges in the COVID product line [5] - The company raised its adjusted diluted EPS guidance for the full year 2025, reflecting strong performance and efficient cost structure [33] - Management noted that the agreement with the U.S. Government will have a diluted impact on the 2026 financial outlook but does not affect the 2025 guidance [32] Other Important Information - The company expects to achieve $1.5 billion in savings from the manufacturing optimization program by the end of 2027 [26] - Total adjusted operating expenses for Q3 were $7 billion, an increase of 21% operationally compared to last year, largely due to acquired in-process R&D expenses from the 3SBio transaction [28] - The company plans to continue investing in key products and markets to offset losses from upcoming LOEs [25] Q&A Session Summary Question: Insights on VYNDAMAX performance amid competition - Management acknowledged new competition but emphasized VYNDAMAX's unique benefits and strong market access, noting that volume growth was offset by gross-to-net headwinds [40][41] Question: Legal process regarding Metsera acquisition - Management refrained from discussing specific legal timelines but reiterated their belief that Novo's acquisition attempt is anti-competitive [47][49] Question: Plans if Metsera acquisition does not proceed - Management indicated ongoing efforts to identify potential acquisition candidates across therapeutic areas, emphasizing a proactive approach to business development [51][53] Question: Impact of manufacturing investments under the MFN agreement - Management highlighted the importance of investing in U.S. production while also improving operational cost efficiencies [59][61] Question: Clarification on PAXLOVID pricing dynamics - Management noted no significant change in pricing but acknowledged variations in channel mix affecting sales [76] Question: Guidance on COVID-19 sales for the year - Management expressed cautious optimism regarding COVID-19 sales, noting potential spikes in utilization due to future waves of the virus [88]

Financial Data and Key Metrics Changes - For Q3 2025, the company recorded revenues of $16.7 billion, a decrease of 7% operationally compared to the same period last year, primarily driven by a decline in COVID products, particularly Paxlovid [20][21] - Reported diluted earnings per share (EPS) was $0.62, while adjusted diluted EPS was $0.87, exceeding expectations due to strong gross margin and cost management performance [21][24] - Adjusted gross margin for Q3 was approximately 76%, reflecting product mix and strong cost management within the manufacturing footprint [22] Business Line Data and Key Metrics Changes - The non-COVID product performance was solid, growing 4% operationally compared to the same period last year, with strong contributions from Eliquis, the Vyndaqel family, and Nurtec [20][21] - The Vyndaqel family achieved 7% year-over-year global operational growth, while Padcev saw 13% year-over-year global operational growth [12][13] - The vaccines portfolio, particularly the Prevnar family, achieved 17% year-over-year international operational growth [15] Market Data and Key Metrics Changes - In international markets, the company achieved 40% growth in total patients on treatment for the Vyndaqel family [12] - The U.S. market saw double-digit demand growth for the Vyndaqel family, reflecting strong diagnostic efforts and broad access [12][13] - The company experienced a year-over-year decline in the U.S. for Prevnar 20, attributed to delayed government bulk orders [15][16] Company Strategy and Development Direction - The company is focused on strategic investments in future innovation and growth, highlighted by the proposed acquisition of MedSera and the licensing agreement with 3SBio [4][5] - The company aims to enhance its R&D pipeline and commercial capabilities, particularly in the cardiometabolic area and oncology [6][8] - The recent agreement with the U.S. government is expected to lower prescription drug costs and provide clarity for future investments [29] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's position to deliver value for patients and shareholders, despite challenges in the COVID product line [4][18] - The company raised its adjusted diluted EPS guidance for the full year 2025, reflecting strong performance and improved cost structure [30] - Management noted that the agreement with the U.S. government will not impact 2025 guidance but may have a diluted effect on 2026 financial outlook [29] Other Important Information - The company expects to achieve $1.5 billion in savings from the manufacturing optimization program by the end of 2027 [23][25] - The MedSera acquisition is expected to be funded through a mix of available cash and debt, with anticipated dilution to adjusted EPS in 2026 [26][27] - The company plans to continue investing in R&D and business development to enhance its product portfolio and pipeline [30] Q&A Session Summary Question: Comments on Vyndamax performance amid competition - Management acknowledged new competition but emphasized Vyndamax's unique benefits and strong market share, despite some gross-to-net headwinds impacting net sales [32][35] Question: Legal process regarding MedSera acquisition - Management stated that it is difficult to comment on the timing of legal proceedings but reiterated the belief that Novo's acquisition attempt is anti-competitive [38][39] Question: Plans if MedSera acquisition does not proceed - Management indicated that the company has significant resources and will continue to pursue business development opportunities across therapeutic areas [39][40] Question: Impact of manufacturing investments under the MFN agreement - Management highlighted the importance of both manufacturing investments and operational cost efficiencies, indicating that both will be prioritized [42][43] Question: Guidance for total COVID-19 sales - Management acknowledged the uncertainty in COVID-19 sales but reiterated confidence in achieving the overall revenue guidance range [49] Question: Pricing dynamics for GLP-1 medications - Management acknowledged that competition may drive prices down but indicated that their calculations for the MedSera acquisition took potential pricing declines into account [51] Question: Delay in initiation of pivotal trial for pneumococcal program - Management explained that the timing of the trial initiation is contingent on FDA alignment and that they are coordinating pediatric and adult studies [52][53]